Latest Breaking News On - Radek spisek - Page 1 : comparemela.com

Synaffix partners with SOTIO Biotech in deal worth up to $740m

Synaffix partners with SOTIO Biotech in deal worth up to $740m
pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.

Radek spisek

After halting lead asset, Sotio signs $740M deal with Synaffix

After halting lead asset, Sotio signs $740M deal with Synaffix
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Noord hollandRadek spisekSotio biotechCzech republic headquartered sotioBig pharma

SOTIO expands ADC pipeline with Synaffix tie up

Synaffix, a Lonza company commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has entered a licensing agreement with SOTIO, a clinical stage immuno-oncology company owned by PPF Group.

Radek spisekMarkets amp regulationsAntibody drug conjugatesLicensing agreement

SOTIO Enters Licensing Agreement With Synaffix to Expand ADC Pipeline

SOTIO Enters Licensing Agreement With Synaffix to Expand ADC Pipeline
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Noord hollandLepu biopharmaMicrotubule synstatinPrnewswire synaffixEli lillyInnovent biologicsMicrotubule syntansineChong kun dang pharmaRadek spisekPlatform technologyCapsules health ingredientsAntibody drug conjugateChief executive officerMersana therapeuticsShanghai miracogenKyowa kirin

SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix s ADC Technology

SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical needCollaboration bolsters SOTIO’s wider portfolio of differentiated immuno-oncology therapies tailored to address the specific challenges of solid tumorsSynaffix wi.

Eli lillyLepu biopharmaChong kun dang pharmaRadek spisekInnovent biologicsRichard kapsaMartin steegmaierMersana therapeuticsShanghai miracogenKyowa kirinEmergence therapeuticsHummingbird biosciences